<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: This study aimed to evaluate the effect of a <z:chebi fb="0" ids="50218">phosphodiesterase inhibitor</z:chebi>, cilostazol, on the prevention of silent <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> in diabetic patients without symptoms of vascular events </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A total of 89 subjects were allocated at random to the cilostazol group ( n = 43) or the control group ( n = 46) </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: After the study period (3.2 +/- 0.5 years), carotid intima-media thickness (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e>) (means +/- SD) had increased ( p &lt; 0.01) by 0.18 +/- 0.19 mm in the control group </plain></SENT>
<SENT sid="3" pm="."><plain>In the cilostazol group, intima-media thickness showed almost no change (-0.00 +/- 0.16 mm) </plain></SENT>
<SENT sid="4" pm="."><plain>In the control group, 2 out of 46 subjects showed symptomatic <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarctions</z:e> and 10 out of 34 subjects without <z:mpath ids='MPATH_124'>infarct</z:mpath>-like region assessed by standard brain MRI examination showed silent <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarctions</z:e> after the observation period </plain></SENT>
<SENT sid="5" pm="."><plain>On the other hand, no subjects in the cilostazol group showed silent <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> or <z:hpo ids='HP_0001297'>strokes</z:hpo> during the study period </plain></SENT>
<SENT sid="6" pm="."><plain>Both at the beginning and end of the study period, the number of <z:mpath ids='MPATH_124'>infarct</z:mpath>-like regions positively correlated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> ( r = 0.335, p &lt; 0.001 or r = 0.347, p &lt; 0.001 respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>The progression of <z:mpath ids='MPATH_124'>infarct</z:mpath>-like regions was directly related to the increase in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> during the study period ( r = 0.299, p = 0.004) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION/INTERPRETATION: These data demonstrated that cilostazol could prevent the <z:hpo ids='HP_0003674'>onset</z:hpo> of silent <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> in Japanese subjects with Type II (non-insulin-dependent) <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Also, an increase in intima-media thickness of the carotid artery wall could be able to predict the <z:hpo ids='HP_0003674'>onset</z:hpo> of silent <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> </plain></SENT>
</text></document>